Correction to: Nature Reviews Cancer, published online 2 May 2024

In the version of the article initially published, in the second paragraph of the “Conclusion and future perspectives” section, “PD-L1” has been corrected to “PD-1” in the text now reading “PD-1 inhibitors nivolumab or pembrolizumab”. Additionally, in the Acknowledgements section, A. Durbin’s name was misspelt. These errors have now been corrected in the HTML and PDF versions of the article.